JP2023509336A5 - - Google Patents
Info
- Publication number
- JP2023509336A5 JP2023509336A5 JP2022535637A JP2022535637A JP2023509336A5 JP 2023509336 A5 JP2023509336 A5 JP 2023509336A5 JP 2022535637 A JP2022535637 A JP 2022535637A JP 2022535637 A JP2022535637 A JP 2022535637A JP 2023509336 A5 JP2023509336 A5 JP 2023509336A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use described
- neovascularization
- disorder
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19218062 | 2019-12-19 | ||
| EP19218062.8 | 2019-12-19 | ||
| EP20156158.6 | 2020-02-07 | ||
| EP20156158 | 2020-02-07 | ||
| PCT/EP2020/086993 WO2021123142A1 (en) | 2019-12-19 | 2020-12-18 | Compounds for treatment of eye diseases associated with excessive vascularisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509336A JP2023509336A (ja) | 2023-03-08 |
| JP2023509336A5 true JP2023509336A5 (cg-RX-API-DMAC7.html) | 2023-12-26 |
| JP7730816B2 JP7730816B2 (ja) | 2025-08-28 |
Family
ID=74141502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535637A Active JP7730816B2 (ja) | 2019-12-19 | 2020-12-18 | 過剰血管新生に関連する眼疾患を治療する化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11478465B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3886858B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7730816B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114845718B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020408179B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009192A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3157394A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3886858T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2921360T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293469B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022006439A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3886858T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021123142A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202204939B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CA3157394A1 (en) * | 2019-12-19 | 2021-06-24 | Helena ERIKSSON | Compounds for treatment of eye diseases associated with excessive vascularisation |
| AU2022248724A1 (en) | 2021-04-01 | 2023-11-02 | Active Biotech Ab | Laquinimod formulation for ocular use |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| EP4734995A1 (en) * | 2023-06-28 | 2026-05-06 | Board of Regents, The University of Texas System | Quinoline carboxamides for use in the treatment of mpn |
| CN117256554A (zh) * | 2023-09-08 | 2023-12-22 | 益诺思生物技术南通有限公司 | 一种c57bl/6j小鼠新生血管型眼病模型及其构建方法 |
| KR102925647B1 (ko) * | 2023-10-13 | 2026-02-11 | 재단법인 대구경북첨단의료산업진흥재단 | 안질환 치료제 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| WO2010070449A2 (en) | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| AU2011274496B2 (en) * | 2010-07-09 | 2016-03-10 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| SG10201606191PA (en) | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| EP2844268A4 (en) * | 2012-04-20 | 2015-11-25 | Univ Howard | METHOD FOR THE TREATMENT OF EYE DISEASE AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASE |
| WO2013173307A1 (en) * | 2012-05-16 | 2013-11-21 | Neil Desai | Multi-target modulation for treating fibrosis and inflammatory conditions |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| AU2013342275B2 (en) * | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| CN105163730B (zh) * | 2013-01-08 | 2018-10-30 | 帕萨罗杰卡有限公司 | 用于治疗脱髓鞘疾病的方法和组合物 |
| BR112016000177A2 (pt) * | 2013-07-11 | 2017-12-12 | Novartis Ag | usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta |
| WO2015060812A1 (en) | 2013-10-21 | 2015-04-30 | Howard University | Treating ocular disease with efflux transporter inhibitors |
| WO2015073697A1 (en) * | 2013-11-15 | 2015-05-21 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| EP3082761A2 (en) * | 2013-12-20 | 2016-10-26 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
| WO2017120355A1 (en) | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| CN108778330A (zh) * | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| US10905770B2 (en) * | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| MA51327A (fr) | 2017-12-22 | 2021-05-26 | Chemocentryx Inc | Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar |
| MX2020006459A (es) | 2017-12-22 | 2020-11-06 | Chemocentryx Inc | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. |
| ES2993034T3 (en) | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
| CA3157394A1 (en) * | 2019-12-19 | 2021-06-24 | Helena ERIKSSON | Compounds for treatment of eye diseases associated with excessive vascularisation |
-
2020
- 2020-12-18 CA CA3157394A patent/CA3157394A1/en active Pending
- 2020-12-18 EP EP20838435.4A patent/EP3886858B1/en active Active
- 2020-12-18 PL PL20838435.4T patent/PL3886858T3/pl unknown
- 2020-12-18 ES ES20838435T patent/ES2921360T3/es active Active
- 2020-12-18 EP EP22167643.0A patent/EP4094765A1/en not_active Withdrawn
- 2020-12-18 JP JP2022535637A patent/JP7730816B2/ja active Active
- 2020-12-18 CN CN202080087752.XA patent/CN114845718B/zh active Active
- 2020-12-18 DK DK20838435.4T patent/DK3886858T3/da active
- 2020-12-18 WO PCT/EP2020/086993 patent/WO2021123142A1/en not_active Ceased
- 2020-12-18 BR BR112022009192A patent/BR112022009192A2/pt unknown
- 2020-12-18 AU AU2020408179A patent/AU2020408179B2/en active Active
- 2020-12-18 IL IL293469A patent/IL293469B2/en unknown
- 2020-12-18 MX MX2022006439A patent/MX2022006439A/es unknown
-
2021
- 2021-07-02 US US17/366,979 patent/US11478465B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04939A patent/ZA202204939B/en unknown
- 2022-09-07 US US17/939,109 patent/US12208091B2/en active Active